Literature DB >> 26211948

Aiming for allosterism: Evaluation of allosteric modulators of CB1 in a neuronal model.

Alex Straiker1, José Mitjavila2, Danielle Yin2, Anne Gibson2, Ken Mackie2.   

Abstract

Cannabinoid pharmacology has proven nettlesome with issues of promiscuity a common theme among both agonists and antagonists. One recourse is to develop allosteric ligands to modulate cannabinoid receptor signaling. Cannabinoids have come late to the allosteric table. The 'first-generation' negative and positive allosteric modulators (NAMs and PAMs) represent an important first effort. However, most studies have relied on synthetic agonists, often tested in over-expression systems rather than a defined neuronal model system that utilizes endogenously synthesized and released cannabinoids. We have systematically examined first-generation NAMs and a PAM on endocannabinoid modulation of synaptic transmission in cultured autaptic hippocampal neurons. These neurons exhibit CB1 and 2-arachidonoyl glycerol (2-AG)-mediated depolarization induced suppression of excitation (DSE) and therefore serve as a model to test CB1 modulators in a neuronal model of endogenous cannabinoid signaling. We find ORG27569, PSNCBAM-1, and PEPCAN12 attenuate DSE and do not directly inhibit CB1 receptors. Of these PSNCBAM-1 is the most efficacious while PEPCAN12 has the distinction of being an endogenous NAM. The reported NAMs pregnenolone and hemopressin as well as the reported PAM lipoxin A4 are without effect in this model of endocannabinoid signaling. In summary, three of the allosteric modulators evaluated function in a manner consistent with allosterism in a neuronal 2-AG-based model of endogenous cannabinoid signaling.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allosteric; Allosterism; Cannabinoid; Depolarization-induced suppression of excitation; Excitatory postsynaptic current; Orthosteric; Tetrahydrocannabinol

Mesh:

Substances:

Year:  2015        PMID: 26211948      PMCID: PMC4574285          DOI: 10.1016/j.phrs.2015.07.017

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  28 in total

Review 1.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

2.  Hemopressin is an inverse agonist of CB1 cannabinoid receptors.

Authors:  Andrea S Heimann; Ivone Gomes; Camila S Dale; Rosana L Pagano; Achla Gupta; Laura L de Souza; Augusto D Luchessi; Leandro M Castro; Renata Giorgi; Vanessa Rioli; Emer S Ferro; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-12       Impact factor: 11.205

3.  CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity.

Authors:  Gemma L Baillie; James G Horswill; Sharon Anavi-Goffer; Patricia H Reggio; Daniele Bolognini; Mary E Abood; Sean McAllister; Phillip G Strange; Gary J Stephens; Roger G Pertwee; Ruth A Ross
Journal:  Mol Pharmacol       Date:  2012-11-15       Impact factor: 4.436

4.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

5.  Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons.

Authors:  Tarun Jain; Jim Wager-Miller; Ken Mackie; Alex Straiker
Journal:  Mol Pharmacol       Date:  2013-06-07       Impact factor: 4.436

6.  Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

Authors:  Eric J Topol; Marie-Germaine Bousser; Keith A A Fox; Mark A Creager; Jean-Pierre Despres; J Donald Easton; Christian W Hamm; Gilles Montalescot; P Gabriel Steg; Thomas A Pearson; Eric Cohen; Christophe Gaudin; Bernard Job; Judith H Murphy; Deepak L Bhatt
Journal:  Lancet       Date:  2010-08-14       Impact factor: 79.321

7.  Real-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.

Authors:  Erin E Cawston; William J Redmond; Courtney M Breen; Natasha L Grimsey; Mark Connor; Michelle Glass
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

8.  Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors.

Authors:  Mark Bauer; Andrea Chicca; Marco Tamborrini; David Eisen; Raissa Lerner; Beat Lutz; Oliver Poetz; Gerd Pluschke; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

9.  Pregnenolone can protect the brain from cannabis intoxication.

Authors:  Monique Vallée; Sergio Vitiello; Luigi Bellocchio; Etienne Hébert-Chatelain; Stéphanie Monlezun; Elena Martin-Garcia; Fernando Kasanetz; Gemma L Baillie; Francesca Panin; Adeline Cathala; Valérie Roullot-Lacarrière; Sandy Fabre; Dow P Hurst; Diane L Lynch; Derek M Shore; Véronique Deroche-Gamonet; Umberto Spampinato; Jean-Michel Revest; Rafael Maldonado; Patricia H Reggio; Ruth A Ross; Giovanni Marsicano; Pier Vincenzo Piazza
Journal:  Science       Date:  2014-01-03       Impact factor: 47.728

10.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor.

Authors:  Fabricio A Pamplona; Juliano Ferreira; Octávio Menezes de Lima; Filipe Silveira Duarte; Allisson Freire Bento; Stefânia Forner; Jardel G Villarinho; Luigi Bellocchio; Luigi Bellochio; Carsten T Wotjak; Raissa Lerner; Krisztina Monory; Beat Lutz; Claudio Canetti; Isabelle Matias; João Batista Calixto; Giovanni Marsicano; Marilia Z P Guimarães; Reinaldo N Takahashi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

View more
  32 in total

Review 1.  Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.

Authors:  Leepakshi Khurana; Ken Mackie; Daniele Piomelli; Debra A Kendall
Journal:  Neuropharmacology       Date:  2017-05-17       Impact factor: 5.250

2.  The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB1 receptor allosteric modulators.

Authors:  Thomas F Gamage; Charlotte E Farquhar; Timothy W Lefever; Brian F Thomas; Thuy Nguyen; Yanan Zhang; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2017-08-10       Impact factor: 5.250

3.  Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels.

Authors:  Caitlin E Scott; Debra A Kendall
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

Review 4.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

Review 5.  Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.

Authors:  Thuy Nguyen; Jun-Xu Li; Brian F Thomas; Jenny L Wiley; Terry P Kenakin; Yanan Zhang
Journal:  Med Res Rev       Date:  2016-11-23       Impact factor: 12.944

6.  Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Authors:  Richard A Slivicki; Zhili Xu; Pushkar M Kulkarni; Roger G Pertwee; Ken Mackie; Ganesh A Thakur; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2017-07-08       Impact factor: 13.382

7.  2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity.

Authors:  Leanne Lu; Gareth Williams; Patrick Doherty
Journal:  Cannabis Cannabinoid Res       Date:  2019-12-09

8.  Evidence that cannabinoid CB1 receptors regulate intraocular pressure via two opposing mechanisms.

Authors:  Sally Miller; Laura Daily; Maya Ploss; Iain Greig; Ruth Ross; Naga Pradeep Rayana; Jiannong Dai; Chenna Kesavulu Sugali; Weiming Mao; Alex Straiker
Journal:  Exp Eye Res       Date:  2020-09-14       Impact factor: 3.467

9.  Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.

Authors:  Mylyne Tham; Orhan Yilmaz; Mariam Alaverdashvili; Melanie E M Kelly; Eileen M Denovan-Wright; Robert B Laprairie
Journal:  Br J Pharmacol       Date:  2018-08-10       Impact factor: 8.739

10.  Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons.

Authors:  Alex Straiker; Michaela Dvorakova; Anaelle Zimmowitch; Ken Mackie
Journal:  Mol Pharmacol       Date:  2018-04-18       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.